|
US5208020A
(en)
|
1989-10-25 |
1993-05-04 |
Immunogen Inc. |
Cytotoxic agents comprising maytansinoids and their therapeutic use
|
|
EP0573464B1
(en)
|
1991-02-27 |
1997-03-19 |
Pfizer Inc. |
Process for preparing trans-piperidine-2,5-dicarboxylates
|
|
CA2192725C
(en)
|
1995-12-28 |
2004-04-20 |
Kenji Tsujihara |
Camptothecin derivatives
|
|
WO2003000657A1
(en)
|
2001-06-20 |
2003-01-03 |
Daiichi Pharmaceutical Co., Ltd. |
Diamine derivatives
|
|
EP3434275A1
(en)
|
2003-11-06 |
2019-01-30 |
Seattle Genetics, Inc. |
Assay for cancer cells based on the use of auristatin conjugates with antibodies
|
|
EP1701979A2
(en)
|
2003-12-03 |
2006-09-20 |
Xencor, Inc. |
Optimized antibodies that target the epidermal growth factor receptor
|
|
WO2009011285A1
(ja)
|
2007-07-13 |
2009-01-22 |
Taisho Pharmaceutical Co., Ltd. |
ヘテロアリールベンゼン化合物
|
|
BRPI0911652A2
(pt)
|
2008-04-11 |
2015-08-04 |
Merrimack Pharmaceuticals Inc |
Ligantes de albumina sérica humana e seus conjugados
|
|
WO2010019952A2
(en)
|
2008-08-15 |
2010-02-18 |
Merrimack Pharmaceuticals, Inc. |
Methods, systems and products for predicting response of tumor cells to a therapeutic agent and treating a patient according to the predicted response
|
|
CN102282168A
(zh)
|
2008-11-18 |
2011-12-14 |
梅里麦克制药股份有限公司 |
人血清白蛋白接头以及其结合物
|
|
CN102459347A
(zh)
|
2009-05-01 |
2012-05-16 |
雅培制药有限公司 |
双重可变结构域免疫球蛋白及其用途
|
|
TW201109438A
(en)
|
2009-07-29 |
2011-03-16 |
Abbott Lab |
Dual variable domain immunoglobulins and uses thereof
|
|
AR078254A1
(es)
|
2009-09-01 |
2011-10-26 |
Abbott Lab |
Inmunoglobulinas con dominio variable dual y usos de las mismas
|
|
EP2493929B1
(en)
|
2009-10-28 |
2017-08-16 |
AbbVie Biotherapeutics Inc. |
Anti-egfr antibodies and their uses
|
|
UY33492A
(es)
|
2010-07-09 |
2012-01-31 |
Abbott Lab |
Inmunoglobulinas con dominio variable dual y usos de las mismas
|
|
US9051370B2
(en)
|
2010-08-10 |
2015-06-09 |
Glycotope Gmbh |
Humanized EGFR antibodies
|
|
US20120263722A1
(en)
|
2010-11-04 |
2012-10-18 |
Abbott Laboratories |
Dual Variable Domain Immunoglobulins and Uses Thereof
|
|
WO2012088290A2
(en)
|
2010-12-22 |
2012-06-28 |
Abbott Laboratories |
Tri-variable domain binding proteins and uses thereof
|
|
CN103547598A
(zh)
|
2011-02-24 |
2014-01-29 |
梅里麦克制药股份有限公司 |
包含抗-erbb3药剂的联合治疗
|
|
JP2014509593A
(ja)
|
2011-03-15 |
2014-04-21 |
メリマック ファーマシューティカルズ インコーポレーティッド |
ＥｒｂＢ経路阻害剤に対する耐性の克服
|
|
WO2013101993A2
(en)
|
2011-12-30 |
2013-07-04 |
Abbvie Inc. |
Dual variable domain immunoglobulins and uses thereof
|
|
AU2013229786B2
(en)
|
2012-03-08 |
2017-06-22 |
Halozyme, Inc. |
Conditionally active anti-epidermal growth factor receptor antibodies and methods of use thereof
|
|
CN110078827A
(zh)
|
2012-04-27 |
2019-08-02 |
西托姆克斯治疗公司 |
结合表皮生长因子受体的可活化的抗体其使用方法
|
|
EP2847226A4
(en)
|
2012-05-11 |
2016-05-11 |
Merrimack Pharmaceuticals Inc |
DOSAGE AND ADMINISTRATION OF BIS SPECIFIC SCFV CONJUGATES IN COMBINATION WITH ANTICROBIAL AGENTS
|
|
US9546155B2
(en)
|
2012-06-15 |
2017-01-17 |
Mitsubishi Tanabe Pharma Corporation |
Aromatic heterocyclic compound
|
|
KR20150058236A
(ko)
|
2012-08-20 |
2015-05-28 |
글리크닉 인코포레이티드 |
항원 결합 및 다가 fc 감마 수용체 결합 활성을 가진 분자
|
|
WO2014036520A1
(en)
|
2012-08-30 |
2014-03-06 |
Merrimack Pharmaceuticals, Inc. |
Combination therapies comprising anti-erbb3 agents
|
|
WO2014052717A2
(en)
|
2012-09-27 |
2014-04-03 |
Massachusetts Institute Of Technology |
Cd20-and egfr-binding proteins enhanced stability
|
|
WO2014057687A1
(ja)
|
2012-10-11 |
2014-04-17 |
第一三共株式会社 |
抗体－薬物コンジュゲート
|
|
WO2014061277A1
(ja)
|
2012-10-19 |
2014-04-24 |
第一三共株式会社 |
親水性構造を含むリンカーで結合させた抗体－薬物コンジュゲート
|
|
US20140242077A1
(en)
|
2013-01-23 |
2014-08-28 |
Abbvie, Inc. |
Methods and compositions for modulating an immune response
|
|
PL2970512T3
(pl)
|
2013-03-12 |
2019-03-29 |
Biocon Limited |
Immunomodulujące białka fuzyjne i sposoby ich otrzymywania
|
|
WO2014144357A1
(en)
|
2013-03-15 |
2014-09-18 |
Merck Patent Gmbh |
Tetravalent bispecific antibodies
|
|
AU2014262566A1
(en)
|
2013-05-08 |
2015-11-12 |
Zymeworks Inc. |
Bispecific HER2 and HER3 antigen binding constructs
|
|
US9879081B2
(en)
|
2013-06-25 |
2018-01-30 |
Samsung Electronics Co., Ltd. |
Protein complex, bispecific antibody including the protein complex, and method of preparation thereof
|
|
JP6693872B2
(ja)
|
2013-07-25 |
2020-05-13 |
シトムクス セラピューティクス，インコーポレイティド |
多重特異性抗体、多重特異性活性化可能抗体、及びそれらの使用方法
|
|
WO2015038984A2
(en)
|
2013-09-12 |
2015-03-19 |
Halozyme, Inc. |
Modified anti-epidermal growth factor receptor antibodies and methods of use thereof
|
|
US9540440B2
(en)
|
2013-10-30 |
2017-01-10 |
Cytomx Therapeutics, Inc. |
Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof
|
|
WO2015063339A1
(en)
|
2013-11-04 |
2015-05-07 |
Glenmark Pharmaceuticals S.A. |
Production of t cell retargeting hetero-dimeric immunoglobulins
|
|
JP2016538283A
(ja)
|
2013-11-13 |
2016-12-08 |
ザイムワークス，インコーポレイテッド |
Ｅｇｆｒ及び／またはｈｅｒ２を標的にする一価抗原結合性構築物及びその使用
|
|
PT3088419T
(pt)
|
2013-12-25 |
2019-01-11 |
Daiichi Sankyo Co Ltd |
Conjugado de anticorpo anti-trop2-fármaco
|
|
HRP20190431T1
(hr)
|
2014-01-31 |
2019-04-19 |
Daiichi Sankyo Company, Limited |
Anti-her2 antitijelo-lijek konjugat
|
|
WO2015123679A1
(en)
*
|
2014-02-17 |
2015-08-20 |
Seattle Genetics, Inc. |
Hydrophilic antibody-drug conjugates
|
|
CN111228511B
(zh)
|
2014-04-10 |
2024-06-18 |
第一三共株式会社 |
抗her3抗体-药物偶联物
|
|
ES2754348T3
(es)
*
|
2014-04-10 |
2020-04-17 |
Daiichi Sankyo Co Ltd |
Conjugado de (anticuerpo anti-HER2)-fármaco
|
|
US10328149B2
(en)
|
2014-06-13 |
2019-06-25 |
Tenboron Oy |
Conjugates comprising an anti-EGFR1 antibody
|
|
KR20170068409A
(ko)
|
2014-09-16 |
2017-06-19 |
이즈 참 리미티드 |
항-egfr 항체 및 그의 용도
|
|
CN104403004B
(zh)
|
2014-11-24 |
2017-10-13 |
苏州丁孚靶点生物技术有限公司 |
抗体‑干扰素异二聚体的制备和用途
|
|
DK3237005T3
(en)
|
2014-12-22 |
2024-11-18 |
Systimmune Inc |
Bispecific tetravalent antibodies and methods of making and using thereof
|
|
CN105820248A
(zh)
|
2015-01-07 |
2016-08-03 |
上海张江生物技术有限公司 |
一种新型抗egfr单克隆抗体的制备方法及应用
|
|
KR101770559B1
(ko)
|
2015-04-23 |
2017-08-24 |
신일제약주식회사 |
EGFR에 특이적으로 결합하는 Fab 단편
|
|
EP3316907A4
(en)
|
2015-06-01 |
2019-02-13 |
ImmuneXcite, Inc. |
CONTAINS OF BETA-1,6-GLUCAN AND ANTIBODY CÉTUXIMAB
|
|
CN107709356A
(zh)
|
2015-06-26 |
2018-02-16 |
南加利福尼亚大学 |
用于肿瘤特异性活化的掩蔽嵌合抗原受体t细胞
|
|
AU2016301196B2
(en)
|
2015-08-06 |
2022-09-08 |
Dana-Farber Cancer Institute, Inc. |
Tunable endogenous protein degradation
|
|
EP3400248A4
(en)
|
2016-01-10 |
2019-09-04 |
Sorrento Therapeutics, Inc. |
IMPROVED SAFETY FOR THE TREATMENT OF CANCER WITH GLYCOSYLATED CHIMERIC ANTIBODY AGAINST EGFR
|
|
JP7251981B2
(ja)
|
2016-03-24 |
2023-04-04 |
バイエル ファーマ アクチエンゲゼルシャフト |
酵素開裂基を有する細胞毒性活性剤のプロドラッグ
|
|
SG11201809316XA
(en)
|
2016-04-28 |
2018-11-29 |
Biomunex Pharmaceuticals |
Bispecific antibodies targeting egfr and her2
|
|
US11649291B2
(en)
|
2016-05-24 |
2023-05-16 |
Insmed Incorporated |
Antibodies and methods of making same
|
|
WO2018026742A1
(en)
|
2016-08-01 |
2018-02-08 |
Askgene Pharma Inc. |
Novel antibody-albumin-drug conjugates (aadc) and methods for using them
|
|
JP7685735B2
(ja)
|
2016-12-02 |
2025-05-30 |
アンヘレス セラピューティクス インコーポレイテッド |
合成免疫受容体およびその使用方法
|
|
EP3552626A4
(en)
|
2016-12-12 |
2020-06-10 |
Daiichi Sankyo Company, Limited |
ASSOCIATION OF AN ANTIBODY DRUG CONJUGATE AND AN IMMUNE CONTROL POINT INHIBITOR
|
|
CA3047491A1
(en)
|
2016-12-21 |
2018-06-28 |
Bayer Aktiengesellschaft |
Prodrugs of cytotoxic active agents having enzymatically cleavable groups
|
|
GB201705686D0
(en)
|
2017-04-07 |
2017-05-24 |
Centauri Therapeutics Ltd |
Novel compounds and therapeutic uses thereof
|
|
CN108948195B
(zh)
|
2017-05-23 |
2022-05-31 |
胡毅 |
一种抗egfr/pd-l1双靶向抗体、其制备方法及用途
|
|
CN108948206B
(zh)
|
2017-05-23 |
2022-08-23 |
赵磊 |
一种抗egfr/pd-1双靶向抗体、其制备方法及用途
|
|
US20200140547A1
(en)
|
2017-05-26 |
2020-05-07 |
The Johns Hopkins University |
Multifunctional antibody-ligand traps to modulate immune tolerance
|
|
WO2018228442A1
(en)
|
2017-06-14 |
2018-12-20 |
Dingfu Biotarget Co., Ltd. |
Proteinaceous heterodimer and use thereof
|
|
CN113952469A
(zh)
|
2017-06-19 |
2022-01-21 |
四川百利药业有限责任公司 |
一种带酸性自稳定接头的抗体-药物偶联物
|
|
CN109306010B
(zh)
|
2017-07-26 |
2022-07-19 |
石家庄以岭药业股份有限公司 |
表皮生长因子受体抗体及其用途
|
|
US20200216544A1
(en)
|
2017-08-16 |
2020-07-09 |
Dragonfly Therapeutics, Inc. |
Proteins binding nkg2d, cd16, and egfr, hla-e, ccr4, or pd-l1
|
|
WO2019034176A1
(zh)
|
2017-08-18 |
2019-02-21 |
四川百利药业有限责任公司 |
一种喜树碱-抗体偶联物
|
|
KR20250084239A
(ko)
|
2017-08-31 |
2025-06-10 |
다이이찌 산쿄 가부시키가이샤 |
항체-약물 콘주게이트의 개량 제조 방법
|
|
JP7248578B2
(ja)
|
2017-08-31 |
2023-03-29 |
第一三共株式会社 |
抗体－薬物コンジュゲートの新規製造方法
|
|
EP3457139A1
(en)
|
2017-09-19 |
2019-03-20 |
Promise Advanced Proteomics |
Antibody-like peptides for quantifying therapeutic antibodies
|
|
EP3694890A4
(en)
|
2017-10-12 |
2021-11-03 |
Immunowake Inc. |
LIGHT CHAIN ANTIBODY FUSION PROTEIN WITH VEGFR
|
|
CN108220244A
(zh)
|
2018-01-18 |
2018-06-29 |
东北农业大学 |
一种含重组人表皮生长因子受体抗体基因的cho细胞株、筛选方法及其生产工艺
|
|
US10654944B2
(en)
|
2018-04-10 |
2020-05-19 |
Y-Biologics Inc. |
Cell engaging binding molecules
|
|
WO2019232323A1
(en)
|
2018-05-31 |
2019-12-05 |
Board Of Regents, The University Of Texas System |
Bi-specific antibodies and use thereof
|
|
WO2019246392A1
(en)
|
2018-06-22 |
2019-12-26 |
Cugene Inc. |
Cytokine-based bioactivatable drugs and methods of uses thereof
|
|
US20210261649A1
(en)
|
2018-06-29 |
2021-08-26 |
Krystal Biotech, Inc, |
Compositions and methods for antibody delivery
|
|
BR112021004656A2
(pt)
|
2018-09-26 |
2021-06-01 |
Jiangsu Hengrui Medicine Co., Ltd. |
conjugado fármaco-ligante de análogo exatecano, método para preparar o mesmo e aplicação do mesmo
|
|
MY209065A
(en)
|
2018-09-30 |
2025-06-18 |
Jiangsu Hansoh Pharmaceutical Group Co Ltd |
Anti-b7h3 antibody-exatecan analog conjugate and medicinal use thereof
|
|
GB201816553D0
(en)
|
2018-10-10 |
2018-11-28 |
Centauri Therapeutics Ltd |
Novel compounds and therapeutic uses thereof
|
|
GB201816554D0
(en)
|
2018-10-10 |
2018-11-28 |
Centauri Therapeutics Ltd |
Novel compounds and therapeutic uses thereof
|
|
JP7410143B2
(ja)
|
2018-11-01 |
2024-01-09 |
山▲東▼新▲時▼代▲薬▼▲業▼有限公司 |
二重特異性抗体及びその用途
|
|
CN111196855B
(zh)
|
2018-11-19 |
2022-11-15 |
三生国健药业（上海）股份有限公司 |
抗egfr/pd-1双特异性抗体
|
|
JP2022510218A
(ja)
|
2018-11-30 |
2022-01-26 |
メモリアル スローン ケタリング キャンサー センター |
ヘテロ二量体四価特異性抗体およびこれらの使用
|
|
US12344646B2
(en)
|
2018-12-13 |
2025-07-01 |
Bang DING |
Antibody-TNF α fusion protein and its preparation and applications
|
|
CN113677703A
(zh)
|
2018-12-17 |
2021-11-19 |
鳄鱼生物科学公司 |
多肽
|
|
WO2020138487A1
(ja)
|
2018-12-28 |
2020-07-02 |
協和キリン株式会社 |
ＴｆＲに結合するバイスペシフィック抗体
|
|
CN111689980A
(zh)
*
|
2019-05-26 |
2020-09-22 |
四川百利药业有限责任公司 |
一种喜树碱药物及其抗体偶联物
|
|
WO2020244657A1
(zh)
|
2019-06-06 |
2020-12-10 |
上海翰森生物医药科技有限公司 |
抗b7-h4抗体-药物偶联物及其医药用途
|
|
CN110256583B
(zh)
|
2019-07-11 |
2022-05-20 |
中国科学院生物物理研究所 |
一种il-2突变体与抗体的融合蛋白及其应用
|
|
CN118221825A
(zh)
|
2019-07-26 |
2024-06-21 |
Abl生物公司 |
抗egfr/抗4-1bb双特异性抗体、用途、制备方法及编码多核苷酸
|
|
CN110669132B
(zh)
|
2019-08-19 |
2023-03-31 |
天津大学前沿技术研究院 |
一种提高IgG1抗体产量的方法
|
|
AU2020347715A1
(en)
|
2019-09-18 |
2022-04-07 |
Systimmune, Inc. |
Camptothecin derivative and conjugate thereof
|
|
CN114616031A
(zh)
|
2019-09-19 |
2022-06-10 |
Igm生物科学股份有限公司 |
对靶标密度高的细胞的选择性增强的多聚体抗体
|
|
AU2020402006A1
(en)
|
2019-12-12 |
2022-07-07 |
Jiangsu Hengrui Medicine Co., Ltd. |
Anti-claudin antibody-drug conjugate and pharmaceutical use thereof
|
|
JP7827624B2
(ja)
|
2019-12-16 |
2026-03-10 |
江蘇恒瑞医薬股▲ふん▼有限公司 |
抗ｃｅａ抗体－エキサテカン類似体複合体及びその医薬用途
|
|
TWI891714B
(zh)
|
2020-01-22 |
2025-08-01 |
大陸商江蘇恆瑞醫藥股份有限公司 |
抗trop-2抗體-依喜替康類似物偶聯物及其醫藥用途
|
|
CN115485300A
(zh)
|
2020-02-26 |
2022-12-16 |
索伦托药业有限公司 |
具有通用掩蔽部分的可活化的抗原结合蛋白
|
|
CN113388631B
(zh)
|
2020-03-12 |
2022-08-09 |
天津大学 |
一种高产IgG1的重组菌及构建方法
|
|
CN115298220B
(zh)
|
2020-03-24 |
2024-12-20 |
上海翰森生物医药科技有限公司 |
抗体-药物偶联物及其医药用途
|
|
WO2021190581A1
(zh)
|
2020-03-25 |
2021-09-30 |
江苏恒瑞医药股份有限公司 |
一种含抗体药物偶联物的药物组合物及其用途
|
|
US20230140397A1
(en)
|
2020-03-25 |
2023-05-04 |
Jiangsu Hengrui Pharmaceuticals Co., Ltd. |
Anti-psma antibody-exatecan analogue conjugate and medical use thereof
|
|
TWI904149B
(zh)
|
2020-03-25 |
2025-11-11 |
大陸商江蘇豪森藥業集團有限公司 |
Ｂ７ｈ３抗體-依喜替康類似物偶聯物及其醫藥用途
|
|
JP7730836B2
(ja)
|
2020-03-25 |
2025-08-28 |
江蘇恒瑞医薬股▲ふん▼有限公司 |
抗体薬物複合体の調製方法
|
|
CN115279781B
(zh)
|
2020-03-26 |
2025-05-09 |
上海翰森生物医药科技有限公司 |
抗体药物偶联物及其医药用途
|
|
US10994021B1
(en)
|
2020-04-11 |
2021-05-04 |
Bliss Biopharmaceutical (Hangzhou) Co., Ltd. |
Tetravalent antibody-drug conjugates and use thereof
|
|
CN113563473A
(zh)
|
2020-04-29 |
2021-10-29 |
三生国健药业（上海）股份有限公司 |
四价双特异性抗体、其制备方法和用途
|
|
CN113754771A
(zh)
|
2020-06-02 |
2021-12-07 |
三生国健药业（上海）股份有限公司 |
一种抗pdl1×egfr的双特异性抗体
|
|
WO2021249228A1
(zh)
*
|
2020-06-08 |
2021-12-16 |
四川百利药业有限责任公司 |
一种带有高稳定性亲水连接单元的喜树碱类药物及其偶联物
|
|
CN111848806B
(zh)
|
2020-06-18 |
2022-06-10 |
广东安普泽生物医药股份有限公司 |
Egfr-cd3双功能抗体及其应用
|
|
CA3184724A1
(en)
|
2020-07-27 |
2022-02-03 |
Wenming REN |
Anti-cd79b antibody-drug conjugate, and preparation method therefor and pharmaceutical use thereof
|
|
JP7780953B2
(ja)
|
2020-09-15 |
2025-12-05 |
バイリ－バイオ（チェンドゥ）ファーマスーティカル シーオー．，エルティーディー． |
カンプトテシン類医薬品及びその抗体複合体
|
|
AU2021354827A1
(en)
|
2020-09-30 |
2023-06-01 |
Jiangsu Hengrui Pharmaceuticals Co., Ltd. |
Pharmaceutical composition comprising antibody-drug conjugate, and use of pharmaceutical composition
|
|
AU2021359457A1
(en)
*
|
2020-10-12 |
2023-05-11 |
Systimmune, Inc. |
Camptothecin derivative and its ligand-drug conjugate
|
|
EP4227309A4
(en)
*
|
2020-10-12 |
2024-11-27 |
Sichuan Baili Pharmaceutical Co. Ltd. |
DEUTERATED CAMPTOTHECIN DERIVATIVE AND ANTIBODY-DRUG CONJUGATE THEREOF
|
|
CN122011191A
(zh)
|
2020-10-14 |
2026-05-12 |
苏州盛迪亚生物医药有限公司 |
抗her3抗体和抗her3抗体药物偶联物及其医药用途
|
|
WO2022099762A1
(zh)
|
2020-11-12 |
2022-05-19 |
博瑞生物医药（苏州）股份有限公司 |
一种抗体偶联物中间体及其制备方法
|
|
CN114569739A
(zh)
|
2020-12-01 |
2022-06-03 |
正大天晴药业集团股份有限公司 |
抗体药物偶联物
|
|
MX2023008716A
(es)
|
2021-02-05 |
2023-08-02 |
Sichuan Kelun Biotech Biopharmaceutical Co Ltd |
Compuesto de camptotecina, metodo de preparacion del mismo y aplicacion del mismo.
|
|
WO2022166719A1
(zh)
|
2021-02-08 |
2022-08-11 |
四川百利药业有限责任公司 |
一种ca4衍生物及其配体-药物偶联物
|
|
TW202300148A
(zh)
|
2021-03-17 |
2023-01-01 |
大陸商江蘇恒瑞醫藥股份有限公司 |
喜樹鹼衍生物的製備方法
|
|
CN115192732B
(zh)
|
2021-04-01 |
2025-02-18 |
成都百利多特生物药业有限责任公司 |
一种dna毒性二聚体化合物及其偶联物
|
|
BR112023022098A2
(pt)
|
2021-04-26 |
2023-12-19 |
Jiangsu Hengrui Pharmaceuticals Co Ltd |
Anticorpo anti-nectina-4 e conjugado anticorpo-fármaco anti-nectina-4 e uso medicinal dos mesmos
|
|
CN113816969B
(zh)
|
2021-04-30 |
2024-01-16 |
联宁（苏州）生物制药有限公司 |
依喜替康类化合物、其抗体药物偶联物及其应用
|
|
IL308246A
(en)
|
2021-05-07 |
2024-01-01 |
Alx Oncology Inc |
Exataxane derivatives and antibody-drug conjugates thereof
|
|
CN117693365A
(zh)
|
2021-06-25 |
2024-03-12 |
同宜医药（苏州）有限公司 |
配体药物偶联物及其应用
|
|
US12545716B2
(en)
|
2021-07-19 |
2026-02-10 |
Immunome, Inc. |
Immunoconjugates and methods
|
|
JP2024536798A
(ja)
|
2021-09-23 |
2024-10-08 |
シャンハイ ハンソー バイオメディカル カンパニー リミテッド |
抗体薬物コンジュゲート並びにその製造方法及び医薬用途
|
|
CN115850291B
(zh)
|
2021-09-24 |
2024-11-15 |
石药集团巨石生物制药有限公司 |
喜树碱衍生物及其用途
|
|
US11814394B2
(en)
|
2021-11-16 |
2023-11-14 |
Genequantum Healthcare (Suzhou) Co., Ltd. |
Exatecan derivatives, linker-payloads, and conjugates and thereof
|
|
WO2023088382A1
(zh)
|
2021-11-17 |
2023-05-25 |
石药集团巨石生物制药有限公司 |
抗体-药物偶联物及其用途
|
|
AU2022402061A1
(en)
|
2021-12-03 |
2024-07-11 |
Systimmune, Inc. |
Anti-human trop2 antibody-camptothecin drug conjugate and medical use thereof
|
|
KR20240120744A
(ko)
|
2021-12-16 |
2024-08-07 |
맵웰 (상하이) 바이오사이언스 컴퍼니, 리미티드 |
캄프토테신 화합물 및 이의 접합체
|
|
KR20240125927A
(ko)
|
2021-12-28 |
2024-08-20 |
베이진 스위찰랜드 게엠베하 |
항체 약물 접합체
|